Special Issue

Pharmacotherapy of Inflammatory Bowel Disease, 2nd Edition

Message from the Guest Editor

Successful treatment of Inflammatory Bowel Diseases (IBD) is characterised by two challenges: the wide range of miscellaneous clinical manifestations requiring individual therapeutic strategies and the permanent advent of novel therapeutic compounds. Given the ongoing scientific work on the pathogenesis of IBD, development of pharmacological immune modulation has become a predominant focus for research groups and the pharmaceutical industry. Starting with classic immunosuppressants, the development of antibodies, oligonucelotides, and, more recently, small molecules has substantially expanded the range of pharmaceuticals available for IBD. In addition, new insights into traditional drugs have reaffirmed their value as effective remedies in daily clinical practice. Multifaceted new therapeutic options increase the opportunities available to both patients and physicians in clinical practice. The aim of this Special Issue is to provide our readers with concise yet comprehensive and up-to-date reviews on the conservative management of various manifestations of IBD.

Guest Editor

Prof. Dr. Wolfgang Kruis

Clinic for Internal Medicine and Gastroenterology, Protestant Hospital Kalk, University of Cologne, Cologne, Germany

Deadline for manuscript submissions

25 January 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/248948

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

